Skip to content

In the life sciences sector, long-term success is dependent on more than innovation alone. To secure funding, enter strategic alliances, and achieve leadership in competitive markets, companies must protect their innovations by implementing a strategic intellectual property (IP) strategy.

Patents should be the cornerstone of any life science innovator’s business strategy. Across biotechnology, pharmaceuticals, medical devices, diagnostics, robotics, AI, digital health, and advanced therapeutics, patents function as currency and leverage. Patents minimize risk in innovations, safeguarding them against competitors, attracting investors, and enabling licensing opportunities. On the other hand, weak or misaligned patent protection can undermine even the most compelling technology during due diligence.

A thoughtful, integrated patent strategy is more than a legal formality for life science innovators. It’s a vital piece of their business.

LINKS

Read “Why Patent Portfolios are Crucial for Life Science Innovators” authored by David J. Dykeman for Life Science Daily News.

Tags: David Dyke, david dykeman, GT Article, GT Boston
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of David J. Dykeman David J. Dykeman

David Dykeman, who serves as Co-Managing Shareholder of Greenberg Traurig’s Boston office and co-chairs the firm’s global Life Sciences & Medical Technology Group, is a registered patent attorney with more than 22 years of experience in patent and intellectual property law. David’s practice

…

David Dykeman, who serves as Co-Managing Shareholder of Greenberg Traurig’s Boston office and co-chairs the firm’s global Life Sciences & Medical Technology Group, is a registered patent attorney with more than 22 years of experience in patent and intellectual property law. David’s practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology.

David provides strategic patent portfolio development and intellectual property advice for clients including major research institutions, multi-national corporations, and start-up companies. He also performs patent due diligence to assess patent portfolios for venture capital investment, mergers and acquisitions, and licensing opportunities.

An author of over 50 articles and a speaker at over 45 conferences on intellectual property law, David is the founding co-chair of the ABA’s Medical Devices Committee. He was honored as one of Boston’s “40 Under 40” innovative business leaders by the Boston Business Journal and was named to the “40 Medtech Innovators Under 40” list by Medical Device & Diagnostic Industry (MD+DI) Magazine. David has also been named one of the top 250 Patent and Technology Licensing Practitioners in the world by Intellectual Asset Management (IAM) Magazine, an “IP Star” by Managing IP magazine, a “Life Science Star” by LMG Life Sciences, and one of the World’s Leading IP Strategists in the IAM 300.

Read more about David J. Dykeman
Show more Show less
Related Posts
shutterstock_564998500
From Innovation to IPO: A Strategic Checklist for Medtech Companies
May 17, 2026
DNA
Building a Future-Proof IP Strategy for AI in Medtech
May 12, 2026
biotechnology
Israel Practice Attorneys Named Life Science Stars in 2020 LMG Life Sciences Guide
October 25, 2020